[HT-03] ホットトピックス03
Dawn of new era: management of migraine headache

[HT-03-2] Anti-CGRP antibodies

^○David W. Dodick (Mayo Clinic)

Although triptans and some prophylactic medications are currently available, some unmet needs of migraine managements remain to be resolved. Now some lineup of new molecules, devices and methods are developing to be served for practical clinical settings. This symposium will review the new lineups by top headache experts.

David W. Dodick, MD, is Professor of Neurology, Director of the Headache Program, and Director of the Concussion Program at Mayo Clinic in Arizona. He is board certified in Neurology and Vascular Neurology by the American Board of Psychiatry and Neurology and board certified in Headache Medicine by the United Certification of Neurological Subspecialties. Dr. Dodick has authored more than 400 peer-reviewed publications and authored/edited 10 books. He is the Chair of the American Migraine Foundation, Chair of the American Brain Foundation, and Chair of the International Concussion Society. Dr Dodick is also the Chair of the International Registry for Migraine Research, Co-Chair of the American Registry for Migraine Research, and Chair of the International Headache Society’s Global Patient Advocacy Coalition. He is the Co-Chair of the International Headache Academy, the American Academy of Neurology (AAN) Annual Program Concussion Committee and Co-Director of the Annual AAN Sports Concussion Conference. He is a former Editor-in-Chief of Cephalalgia, Past-President of the American Headache Society and a Past-President of the International Headache Society.